UW Comprehensive Cancer Center Support
UW Comprehensive Cancer Center Support
批准号:
10626496
负责人:
HOWARD H. BAILEY
金额:
$524.05万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-04-25 至 2028-03-31
关键词:
AccelerationAreaAwardBiological MarkersCancer BurdenCancer CenterCancer ControlCancer ModelCatchment AreaClinicalClinical ResearchCommunicationCommunitiesComprehensive Cancer CenterDevelopmental Therapeutics ProgramDiagnosisEducationEnsureEpigenetic ProcessEquityFacultyFamilyFundingGoalsGrantGrowthHumanImageImmunologicsIncidenceIndividualInfrastructureInnovative TherapyInstitutionInterventionJournalsKnowledgeLeadershipMalignant NeoplasmsManuscriptsMinority GroupsMinority ParticipationMissionNamesNaturePatientsPeer ReviewPersonsPopulationPreventionProviderPublic HealthPublicationsPublishingRadiationResearchResearch InfrastructureResearch PersonnelResearch PriorityResource SharingResourcesSchoolsScienceServicesSocietiesTechnologyTrainingUnderrepresented MinorityUnderserved PopulationUniversitiesWisconsinWorkanticancer researchcancer carecancer geneticscancer imagingcancer preventioncancer therapyequity, diversity, and inclusionevidence basehealth care deliveryimprovedinnovationinter-institutionalmedical schoolsmembermortalitynext generationpopulation basedprogramsrecruittumor microenvironmentvirology
中文摘要
项目摘要/摘要
威斯康星大学碳骨癌中心(UWCCC)寻求在49-53年间继续资助
进一步加快其使命,大幅减少其流域内外的癌症负担-
威斯康星州。UWCCC是威斯康星大学医学院内的矩阵中心
和公共卫生(SMPH),由来自38个系和9个学院的218名教职员工组成
威斯康星大学麦迪逊分校(UW)。我们的成员通过6个月从事癌症护理、研究和教育。
科学计划(人类癌症病毒学、癌症遗传和表观遗传机制、肿瘤
微环境、成像和放射科学、发展治疗学、癌症预防和
控件)由12个共享资源提供支持。在当前赠款期间(2017-2021年),领导层有
成功招募了40名更多样化的新成员,并加强了现有或新的基础设施
促进我们的会员出版3351篇与癌症相关的手稿(31%的方案间或方案内,
53%的机构间),高(≥10)影响因子期刊的比例显著增加(先前拨款,
11%,而目前为23%),增加了我们的NCI研究(直接2017年为1860万美元,2021年为2490万美元)和
研究资助(2017年直接资助7040万美元,2021年资助7630万美元),获得更多多项目奖(P,U),支持
更多的受训者和支持我们扩大集水区的社区。
UWCCC将通过培育一个多样化和支持性的癌症社区,可靠地完成这一使命
基础设施和高效资源。UWCCC致力于减轻我们流域的癌症负担
通过优先研究领域(例如,创新疗法和生物标记物、癌症成像和
扩大基于人群的癌症研究)、增强研究平台(例如,改进的临床研究
基础设施和共享资源),加大努力建设与特派团有关的慈善事业,并扩大地方--
全球合作伙伴关系。
英文摘要
PROJECT SUMMARY/ABSTRACT
The University of Wisconsin Carbone Cancer Center (UWCCC) seeks continued funding for years 49-53 to
further accelerate its mission to dramatically reduce the burden of cancer within and beyond its catchment – the
State of Wisconsin. The UWCCC, which is a matrix center within the University of Wisconsin School of Medicine
and Public Health (SMPH), is composed of 218 faculty members from 38 departments and 9 schools of the
University of Wisconsin-Madison (UW). Our members pursue cancer care, research, and education through 6
scientific programs (Human Cancer Virology, Cancer Genetic and Epigenetic Mechanisms, Tumor
Microenvironment, Imaging and Radiation Sciences, Developmental Therapeutics, and Cancer Prevention and
Control) supported by 12 Shared Resources. During the current grant period (2017-2021), leadership has
successfully recruited >40 new and more diverse members and strengthened existing or new infrastructure
facilitating our membership publishing 3,351 cancer-relevant manuscripts (31% inter- or intra-programmatic,
53% inter-institutional) with a significant increased proportion in high (≥10) impact factor journals (prior grant,
11% compared to current 23%), increasing our NCI research (Direct 2017 $18.6M, 2021 $24.9M) and total
research funding (Direct 2017 $70.4M, 2021 $76.3M), obtaining more multi-project awards (P, U), supporting
more trainees and supporting communities throughout our expanded catchment.
The UWCCC will accomplish this mission through nurturing a diverse and supportive cancer community, reliable
infrastructure, and efficient resources. The UWCCC worked to decrease the burden of cancer in our catchment
and beyond through prioritized research areas (e.g., innovative therapies and biomarkers, cancer imaging, and
expanded population-based cancer research), enhanced research platforms (e.g., improved clinical research
infrastructure and shared resources), increased efforts to build mission-related philanthropy, and expanded local-
to-global partnerships.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)
-
批准号:10620051
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2022
-
负责人:HOWARD H. BAILEY
-
依托单位:
Defining Tumor Microenvironment and Response to Immune Checkpoint Blockade in HIV-related Anogenital Squamous Cell Carcinomas (Immuno/microenvironment)
-
批准号:10620043
-
项目类别:
-
资助金额:$24.47万
-
财政年份:2022
-
负责人:HOWARD H. BAILEY
-
依托单位:
Creating An Efficient Clinical Trial Build System via The Clinical Trials Rapid Activation Consortium (CTRAC)
-
批准号:10227524
-
项目类别:
-
资助金额:$30.02万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10252839
-
项目类别:
-
资助金额:$171.64万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10475114
-
项目类别:
-
资助金额:$165.26万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10004825
-
项目类别:
-
资助金额:$84.54万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
Protocol Specific
-
批准号:8250423
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Clinical Research Central Office
-
批准号:8250421
-
项目类别:
-
资助金额:$32.25万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Program Leaders
-
批准号:8250405
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Program Leaders
-
批准号:7491879
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
Clinical Research Central Office
-
批准号:7491898
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
Protocol Specific
-
批准号:7491902
-
项目类别:
-
资助金额:$13.82万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7607508
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2006
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7375510
-
项目类别:
-
资助金额:$2.11万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE III TRIAL
-
批准号:7204405
-
项目类别:
-
资助金额:$3.86万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7204368
-
项目类别:
-
资助金额:$0.64万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
Chemoprevention of Skin Cancer: Difluoromethylornithine (DFMO) Phase III Trial
-
批准号:7043935
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
-
批准号:8339910
-
项目类别:
-
资助金额:$158.66万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
-
批准号:7943303
-
项目类别:
-
资助金额:$166.4万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
DFMO Prevention Study (2b) in Organ Transplant Subjects
-
批准号:6794941
-
项目类别:
-
资助金额:$25.03万
-
财政年份:2002
-
负责人:HOWARD H. BAILEY
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: